<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02405676</url>
  </required_header>
  <id_info>
    <org_study_id>CCCG-BNHL-2015</org_study_id>
    <nct_id>NCT02405676</nct_id>
  </id_info>
  <brief_title>BNHL-2015 for Children or Adolescents in China</brief_title>
  <acronym>BNHL-2015</acronym>
  <official_title>Treatment Regimen or Children or Adolescent With Mature B-cell NHL or B-AL in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Cancer Group, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science &amp; Technology, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanjing Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Second University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children’s Hospital of Sochow University, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Cancer Group, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether adding 4 injections of rituximab and increasing
      the intensity of chemotherapy regimens in advanced patients can improve the EFS compared with
      the historical study CCCG-NHL-2010.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In our previous study (CCCG-NHL-2010), two-year EFS was 100% for Stage I, 91.3% ± 6.1% for
      Stage II, 75.8% ± 4.4% for Stage III, 56.3% ± 13.5% for Stage IV, and 36.4% ± 14.5% for B-AL,
      respectively. To improve survival for pediatric patients with B-NHL/B-AL, the investigators
      launched a new study in China. Compared with our previous treatment regimens (CCCG-2010),
      patients with stage III and LDH&gt;4 times NL, any stage IV or B-AL were stratified into R4. The
      dose of methotrexate was increased to 5000mg/m2 for patients in R3 or R4 (previously
      3000mg/m2). Four injections of rituximab was added to the chemotherapy for patients in R4.
      Our aim is to test whether adding rituximab or high dose of methotrexate (5000mg/m2) would
      improving 2-year EFS for patients in advanced groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival</measure>
    <time_frame>2 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Mature B-cell Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Risk group 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Complete resection of stage I or II disease: 3 courses (A-B-A) and 3 intrathecal injections(Cytarabine/Methotrexate/Dexamethasone, age adjusted);</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risk group2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Not or incompletely resected stage I/II disease and LDH &lt;2 times NL: 5 courses (A--B--A--B--A) and 8 intrathecal injections;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risk group3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Stage III with high LDH &lt; 4 times NL, or Stage I,II with LDH &gt;=2 times NL: Preface followed by 6 courses (P(Cyclophosphamide/Vincristine/Prednisone)-A-BB-AA-BB-AA-BB) and 13 intrathecal injections; Dosage of Cytarabine, Methotrexate and Etoposide was increased in AA or BB compared with A or B. Vindelsine was used in AA/BB instead of Vincristine in A/B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risk group4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Stage III with LDH≥4N, or Stage IV, or B-AL: Preface followed by 4 dose of rituximab (375mg/m2) combined 6 courses of chemotherapy, together with 13 intrathecal injections: P-A-(Rituximab)BB-(Rituximab)AA-(Rituximab)BB-(Rituximab)AA-BB; rituximab is at D0 of each course.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone,Vincristine, Cyclophosphamide</intervention_name>
    <description>Prednisone 45mg/m2, D1~7; Vincristine 1.5mg/m2(MAX 2mg), D1; Cyclophosphamide 300mg/m2, D1; Intrathecal injection, D1;</description>
    <arm_group_label>Risk group3</arm_group_label>
    <arm_group_label>Risk group4</arm_group_label>
    <other_name>Preface</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone</intervention_name>
    <description>Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1~7;Intrathecal injection, D1,8;</description>
    <arm_group_label>Risk group 1</arm_group_label>
    <arm_group_label>Risk group2</arm_group_label>
    <arm_group_label>Risk group3</arm_group_label>
    <arm_group_label>Risk group4</arm_group_label>
    <other_name>Protocol A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone</intervention_name>
    <description>Ifosphamide 1.2g/m2, D1~5; Etoposide, 60mg/m2, D3~5; Methotrexate, 0.5g/m2, D1;Vincristine 1.5mg/m2 (MAX 2mg), D1; Prednisone 60mg/m2, D1~7;Intrathecal injection, D1;</description>
    <arm_group_label>Risk group 1</arm_group_label>
    <arm_group_label>Risk group2</arm_group_label>
    <other_name>Protocol B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone</intervention_name>
    <description>Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2~4;Vindelsine 3mg/m2 (MAX 5mg), D1; Cytarabine 2g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1~7;Intrathecal injection, D1,8;</description>
    <arm_group_label>Risk group3</arm_group_label>
    <arm_group_label>Risk group4</arm_group_label>
    <other_name>Protocol AA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone</intervention_name>
    <description>Ifosphamide 1.2g/m2, D1~5; Etoposide, 100mg/m2, D3~5; Methotrexate, 5g/m2, D1;Vindelsine 3mg/m2 (MAX 5mg), D1; Prednisone 60mg/m2, D1~7;Intrathecal injection, D1,8;</description>
    <arm_group_label>Risk group3</arm_group_label>
    <arm_group_label>Risk group4</arm_group_label>
    <other_name>Protocol BB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375mg/m2, 4 injections for patients in Risk group4; D0 of Protocol AA or BB;</description>
    <arm_group_label>Risk group4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histology or cytologically confirmed matureB-cell NHL/AL(Burkitt, DLBCL, PMLBL,or
             aggressive mature B-cell NHL non other specified or specifiable)

          -  Able to comply with scheduled follow-up and with management of toxicity

          -  Signed informed consent

        Exclusion Criteria:

          -  Follicular lymphoma, MALT and nodular marginal zone are not included into this
             therapeutic study

          -  Patients with congenital immunodeficiency, chromosomal breakage syndrome, prior organ
             transplantation, previous malignancy of any type, or known positive HIV serology.

          -  -Evidence of pregnancy or lactation period.

               -  Past or current anti-cancer treatment except corticosteroids during less than one
                  week.

        Exclusion criteria related to rituximab:

          -  Tumor cell negative for CD20.

          -  Prior exposure to rituximab.

          -  Hepatitis B carrier status history of HBV or positive serology.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi-Jin Gao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Children's Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi-Jin Gao, MD</last_name>
    <phone>86-21-38626161</phone>
    <phone_ext>82064</phone_ext>
    <email>gaoyijin@scmc.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing-Yan Tang, MD</last_name>
    <email>tangjingyan@scmc.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>West China Second University Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi-Ping Zhu, MD</last_name>
      <email>zhuyiping@918.com</email>
    </contact>
    <contact_backup>
      <last_name>Xia Guo, MD</last_name>
      <email>guoxkl@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Miles RR, Arnold S, Cairo MS. Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia. Br J Haematol. 2012 Mar;156(6):730-43. doi: 10.1111/j.1365-2141.2011.09024.x. Epub 2012 Jan 20. Review.</citation>
    <PMID>22260323</PMID>
  </reference>
  <results_reference>
    <citation>Reiter A, Schrappe M, Tiemann M, Ludwig WD, Yakisan E, Zimmermann M, Mann G, Chott A, Ebell W, Klingebiel T, Graf N, Kremens B, Müller-Weihrich S, Plüss HJ, Zintl F, Henze G, Riehm H. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood. 1999 Nov 15;94(10):3294-306.</citation>
    <PMID>10552938</PMID>
  </results_reference>
  <results_reference>
    <citation>Woessmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B, Oschlies I, Ludwig WD, Klingebiel T, Graf N, Gruhn B, Juergens H, Niggli F, Parwaresch R, Gadner H, Riehm H, Schrappe M, Reiter A; BFM Group. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005 Feb 1;105(3):948-58. Epub 2004 Oct 14.</citation>
    <PMID>15486066</PMID>
  </results_reference>
  <results_reference>
    <citation>Meinhardt A, Burkhardt B, Zimmermann M, Borkhardt A, Kontny U, Klingebiel T, Berthold F, Janka-Schaub G, Klein C, Kabickova E, Klapper W, Attarbaschi A, Schrappe M, Reiter A; Berlin-Frankfurt-Münster group. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol. 2010 Jul 1;28(19):3115-21. doi: 10.1200/JCO.2009.26.6791. Epub 2010 Jun 1.</citation>
    <PMID>20516455</PMID>
  </results_reference>
  <results_reference>
    <citation>Goldman S, Smith L, Anderson JR, Perkins S, Harrison L, Geyer MB, Gross TG, Weinstein H, Bergeron S, Shiramizu B, Sanger W, Barth M, Zhi J, Cairo MS. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. Leukemia. 2013 Apr;27(5):1174-7. doi: 10.1038/leu.2012.255. Epub 2012 Sep 3.</citation>
    <PMID>22940833</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2015</study_first_submitted>
  <study_first_submitted_qc>March 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2015</study_first_posted>
  <last_update_submitted>February 7, 2018</last_update_submitted>
  <last_update_submitted_qc>February 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Cancer Group, China</investigator_affiliation>
    <investigator_full_name>Yi-Jin Gao</investigator_full_name>
    <investigator_title>Shanghai Children's Medical Center, School of Medicine, Shanghai Jiaotong University, Shanghai, China</investigator_title>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>non-Hodgkin</keyword>
  <keyword>B-lymphocytes</keyword>
  <keyword>Child</keyword>
  <keyword>Multicenter study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

